The prevalence of hepatitis C virus infection in Egypt 2015: implications for future policy on prevention and treatment

Liver International

Volumn 37, Issue 1, 2017, Pages 45-53

  Kandeel, Amr ^a   Genedy, Mohamad ^a   El Refai, Samir ^a   Funk, Anna L ^b   Fontanet, Arnaud ^b,c   Talaat, Maha ^d,e  

^a MINISTRY OF HEALTH   (Egypt)

^b INSTITUT PASTEUR   (France)

^c University of Paris Cité   (France)

^d CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^e US Naval Medical Research Unit No3   (Egypt)

Author keywords

hepatitis C Egypt; incidence HCV; nation wide surveys; prevalence HCV

Indexed keywords

HEPATITIS C ANTIBODY; VIRUS RNA;

ADOLESCENT; ADULT; AGING; ARTICLE; BLOOD SAMPLING; CHILD; CHRONIC HEPATITIS C; COMPARATIVE STUDY; CONTROLLED STUDY; DEMOGRAPHY; EGYPT; FEMALE; HEALTH CARE POLICY; HEALTH SURVEY; HEPATITIS C; HUMAN; INFECTION PREVENTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PREVALENCE; SCHISTOSOMIASIS; YOUNG ADULT; AGE DISTRIBUTION; BLOOD; HEPACIVIRUS; INCIDENCE; RISK FACTOR; SEX RATIO;

ADOLESCENT; ADULT; AGE DISTRIBUTION; EGYPT; FEMALE; HEALTH SURVEYS; HEPACIVIRUS; HEPATITIS C; HEPATITIS C ANTIBODIES; HUMANS; INCIDENCE; MALE; MIDDLE AGED; RISK FACTORS; RNA, VIRAL; SEX DISTRIBUTION; YOUNG ADULT;

EID: 84976907269     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.13186     Document Type: Article

References (33)

1. Gower E, Estes C, Blach S, Razavi-Shearer K, Razavi H. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol 2014; 61: S45–57.
2. Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 2013; 57: 1333–42.
3. Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 2006; 45: 529–38.
4. El-Zanaty F, Way A. (2009). Egypt Demographic and Health Survey 2008. Cairo, Egypt: Ministry of Health,El-Zanaty and Associates, and Macro International.
5. Ministry of Health, Egypt, El-Zanaty and Associates, Egypt and ICF International. (2015). Egypt Health Issues Survey 2015. Cairo, Egypt and Rockville, MD: Ministry of Health and ICF International.
6. Newcombe RG. Interval estimation for the difference between independent proportions: comparison of eleven methods. Stat Med 1998; 17: 873–90.
7. Armitage P, Berry G. Statistical Methods in Medical Research, 3rd edn. London: Blackwell, 1994; 131.
8. Gardner MJ, Altman DG. Confidence intervals rather than P values: estimation rather than hypothesis testing. BMJ (Clin Res Ed) 1986; 292: 746–50.
9. Talaat M, El-Sayed N, Kandeel A, et al. Sentinel surveillance for patients with acute hepatitis in Egypt, 2001–04. East Mediterr Health J 2010; 16: 134–40.
10. Centre for Disease Control and Prevention (CDC). Establishment of a viral hepatitis surveillance system – Pakistan, 2009–2011. MMWR Morb Mortal Wkly Rep 2011; 60: 1385–90.
11. MatheÏ C, Buntinx F, Van Damme P. Is the prevalence of hepatitis c virus (HCV) RNA in anti-HCV–positive injection drug users positively correlated with age? J Infect Dis 2001; 184: 659–60.
12. Thein HH, Yi Q, Dore GJ, Krahn MD. Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. Hepatology 2008; 48: 418–31.
13. Breban R, Doss W, Esmat G, et al. Towards realistic estimates of HCV incidence in Egypt. J Viral Hepat 2013; 20: 294–6.
14. Frank C, Mohamed MK, Strickland GT, et al. The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt. Lancet 2000; 355: 887–91.
15. Habib M, Mohamed MK, Abdel-Aziz F, et al. Hepatitis C virus infection in a community in the Nile Delta: risk factors for seropositivity. Hepatology 2001; 33: 248–53.
16. Medhat A, Shehata M, Magder LS, et al. Hepatitis C in a community in Upper Egypt: risk factors for infection. Am J Trop Med Hyg 2002; 66: 633–8.
17. Esmat G, Hashem M, El-Raziky M, et al. Risk factors for hepatitis C virus acquisition and predictors of persistence among Egyptian children. Liver Int 2012; 32: 449–56.
18. Waked I, Doss W, El-Sayed M, et al. The current and future disease burden of chronic hepatitis C virus infection in Egypt. Arab J Gastroentero 2014; 15: 45–52.
19. Ford N, Singh K, Cooke GS, et al. Expanding access to treatment for hepatitis C in resource-limited settings: lessons from HIV/AIDS. Clin Infect Dis 2012; 54: 1465–72.
20. Centre for Disease Control and Prevention (CDC). Progress toward prevention and control of hepatitis c virus infection – Egypt, 2001–2012. MMWR Morb Mortal Wkly Rep 2012; 61: 545–9.
21. El Raziky M, Fathalah WF, Zakaria Z, et al. Predictors of virological response in 3,235 chronic HCV Egyptian patients treated with peginterferon alpha-2a compared with peginterferon alpha-2b using statistical methods and data mining techniques. J Interferon Cytokine Res 2016; 36: 338–46.
22. Deuffic-Burban S, Schwarzinger M, Obach D, et al. Should we await IFN-free regimens to treat HCV genotype 1 treatment-naive patients? A cost-effectiveness analysis (ANRS 95141). Hepatology 2014; 61: 7–14.
23. Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013; 368: 1878–87.
24. Breban R, Arafa N, Leroy S, et al. Effect of preventive and curative interventions on hepatitis C virus transmission in Egypt (ANRS 1211): a modelling study. Lancet Glob Health 2014; 2: e541–9.
25. Negro F. Epidemiology of hepatitis C in Europe. Dig Liver Dis 2014; 46: S158–64.
26. World Health Organization. Hepatitis C. WHO/CDS/CSR/LYO/2003.
27. Espinosa M, Martn-Malo A, Ojeda R, et al. Marked reduction in the prevalence of hepatitis C virus infection in hemodialysis patients: causes and consequences. Am J Kidney Dis 2004; 43: 685–9.
28. Abdel Aziz F, Habib M, Mohamed M, et al. Hepatitis C virus infection in a community in the Nile Delta: population description and HCV prevalence. Hepatology 2000; 32: 111–5.
29. Stoszek SK, Abdel-Hamid M, Narooz S, et al. Prevalence of and risk factors for hepatitis C in rural pregnant Egyptian women. Trans R Soc Trop Med Hyg 2006; 100: 102–7.
30. El Gohary A, Hassan A, Nooman Z, et al. High prevalence of hepatitis C virus among urban and rural population groups in Egypt. Acta Trop 1995; 59: 155–61.
31. Ruane PJ, Ain D, Stryker R, et al. Sofosbuvir plus ribavirin for the treatment of chronic genotype 4 hepatitis C virus infection in patients of Egyptian ancestry. J Hepatol 2015; 62: 1040–6.
32. Obach D, Deuffic-Burban S, Esmat G, et al. Effectiveness and cost-effectiveness of immediate versus delayed treatment of hepatitis C virus-infected patients in a country with limited resources: the case of Egypt. Clin Infect Dis 2014; 58: 1064–71.
33. Obach D, Yazdanpanah Y, Esmat G, et al. How to optimize hepatitis C virus treatment impact on life years saved in resource-constrained countries. Hepatology 2015; 62: 31–9.